Ischemia / Congestive Heart Failure / Myocardial Infarction · Observational Study

Circulating Markers for Ischemic Heart Disease

ClinicalTrials.gov · August 17, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registered observational study designed to evaluate two blood proteins as potential biomarkers in acute myocardial infarction and heart failure. No results are reported in this registry record, and the clinical utility of the biomarkers remains unknown at this stage.

What was studied

Observational. Myocardial Infarction, Ischemia, Congestive Heart Failure; age from 18 Years; accepts healthy volunteers. Intervention: Myocardial Infarction. n = 550. 1 site: United States.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

Until results are published, clinicians should not rely on these biomarkers for clinical decision-making. The study is exploratory and aims to establish whether blood protein levels differ between patients who do and do not develop heart failure.

Plain-language summary

This is an ongoing observational registry study with no results posted; it describes a planned investigation of circulating biomarkers in ischemic heart disease without outcome data or efficacy claims.

Study design

As stated by the source record.

MethodsCase Control model. Prospective time perspective. Primary outcome measure: Hospitalization for acute myocardial infarction, stroke or death (assessed at 3 years)

DesignObservational

PopulationMyocardial Infarction, Ischemia, Congestive Heart Failure; age from 18 Years; accepts healthy volunteers

Sample size550

InterventionMyocardial Infarction

Setting1 site: United States

Reported figures

Quoted from the source exactly as published.

Estimated sample size550

Primary outcome measureHospitalization for acute myocardial infarction, stroke or death

Follow-up duration3 years

Clinical bottom line

Caveats

Results are not posted in this registry record; no outcome data are available.
Study recruitment status is active, so data collection is ongoing.
Primary outcome measures are listed but the analytical approach and statistical plan are not described.
Clinical validity and utility of the two proteins remain unproven; the source explicitly notes detection is 'not known to be associated with any disease or myocardial infarction' at present.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Observational design; no control group or randomization described.

Directness

moderate

Examines circulating proteins in myocardial infarction and heart failure; clinical relevance stated but detection method not yet validated.

Consistency

insufficient

No results reported; consistency with other work cannot be assessed from this registry entry.

Risk of bias

insufficient

No methodology, blinding, or analytical approach reported in registry text.

Sample adequacy

moderate

Estimated enrollment 550 participants; adequate for biomarker discovery but power for clinical outcomes unclear.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT00762333). This is a study registration, not published results. Lead sponsor: UConn Health. Recruitment status: RECRUITING. Study type: OBSERVATIONAL. Enrollment: 550 participants (ESTIMATED). Conditions: Myocardial Infarction, Ischemia, Congestive Heart Failure. Primary outcome measures: Hospitalization for acute myocardial infarction, stroke or death , 3 years. Brief summary: The purpose of this research is to determine if two proteins in the blood are increased during acute myocardial infarction and whether their levels are higher in those who develop heart failure than those who do not. These two proteins are produced and potentially released when the heart muscle is damaged. They may then be released into the blood and be detected by standard method in the research laboratory. At this time, detection of an increase in these proteins in the blood is not known to be associated with any disease or myocardial infarction.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT00762333UConn HealthIschemiaCongestive Heart FailureMyocardial Infarction